Al-Jebari Yahia, Rylander Lars, Ståhl Olof, Giwercman Aleksander
Molecular Reproductive Medicine, Department of Translational Medicine, Lund University, Malmö, Sweden (YA AG).
Unit for Environmental Epidemiology, Division of Occupational and Environmental Medicine, Lund University, Lund, Sweden (LR).
JNCI Cancer Spectr. 2018 Jun 26;2(2):pky027. doi: 10.1093/jncics/pky027. eCollection 2018 Apr.
Increased risk of congenital malformations in children fathered by men treated for cancer might be due to mutagenicity of cancer therapies. Finding of increased malformation prevalence in offspring born before paternal cancer would indicate a treatment-independent mechanism.
Through national registries, we obtained data on singletons born in Sweden from 1994 to 2014 (n = 1 796 160) and their fathers and mothers (1 092 950/1 092 011). Men with cancer (n = 23 932) fathered 26 601 and 9926 children before and after cancer diagnosis, respectively. Associations between paternal cancer, diagnoses retrieved from the Swedish Cancer Register, and offspring malformations, based on Swedish Medical Birth Register data, were estimated by logistic regression.
Children conceived before paternal cancer had a statistically significantly increased risk of all malformations (odds ratio [OR] = 1.08, 95% confidence interval [CI] = 1.02 to 1.15, = .016, 3.8% vs 3.4%) and major malformations (OR = 1.09, 95% CI = 1.01 to 1.18, = .03, 2.4% vs 2.1%). Eye and central nervous system cancers were associated with the highest risk of all malformations (OR = 1.30, 95% CI = 1.04 to 1.61, = .02, 4.5% vs 3.4%). A similar trend was seen for testicular cancer. The malformation rates among children conceived before and after paternal cancer diagnosis were similar.
The association between paternal cancer and risk of malformations in the offspring is not solely due to mutagenic effects of cancer therapy. The increase in prevalence of birth anomalies among children of fathers with malignancy might be due to cancer per se or a common underlying paternal factor, for example, genomic instability.
接受癌症治疗的男性所育子女先天性畸形风险增加,可能归因于癌症治疗的致突变性。在父亲患癌之前出生的后代中畸形患病率增加,这表明存在一种与治疗无关的机制。
通过国家登记处,我们获取了1994年至2014年在瑞典出生的单胎(n = 1796160)及其父母(1092950/1092011)的数据。患癌男性(n = 23932)在癌症诊断前后分别育有26601名和9926名子女。基于瑞典医疗出生登记数据,通过逻辑回归估计父亲患癌、从瑞典癌症登记处检索到的诊断与后代畸形之间的关联。
在父亲患癌之前受孕的子女,所有畸形(优势比[OR] = 1.08,95%置信区间[CI] = 1.02至1.15,P = 0.016,3.8%对3.4%)和主要畸形(OR = 1.09,95% CI = 1.01至1.18,P = 0.03,2.4%对2.1%)的风险在统计学上显著增加。眼癌和中枢神经系统癌与所有畸形的最高风险相关(OR = 1.30,95% CI = 1.04至1.61,P = 0.02,4.5%对3.4%)。睾丸癌也呈现类似趋势。在父亲癌症诊断前后受孕的子女中,畸形率相似。
父亲患癌与后代畸形风险之间的关联并非完全归因于癌症治疗的致突变效应。恶性肿瘤父亲的子女中出生异常患病率的增加,可能归因于癌症本身或共同的潜在父系因素,例如基因组不稳定。